Navigation Links
TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
Date:9/2/2008

identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking stat
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
2. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
3. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
4. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
5. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
6. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
9. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
10. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/17/2014)... and RALEIGH, N.C. , Dec. ... LLC (CTMC), and Integrated Clinical Trial Services, LLC ... retention for clinical trials announce that they have ... Marketing Services (i-CTMS). i-CTMS will provide a broad ... pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... ANF Group, Inc ., a South Florida based ... 170,000-square-foot Joe DiMaggio Children,s Hospital – the first free ... (Photo: http://photos.prnewswire.com/prnh/20110614/FL18288 ) The hospital,s ... designed to earn Gold Leadership in Energy and Environment ...
... June 14, 2011 CVS/pharmacy provides ... at more than 7,200 convenient locations nationwide. Shoppers have come ... larger-than-ever selection of gifts, goods and everyday needs. From popular ... the hottest gear and thoughtful keepsakes perfect for every dad, ...
Cached Medicine Technology:ANF Group, Inc. Completes New Joe DiMaggio Children's Hospital 2Find the Best in Gadgets, Grilling and Grooming in Just One Stop This Father's Day at CVS/pharmacy 2Find the Best in Gadgets, Grilling and Grooming in Just One Stop This Father's Day at CVS/pharmacy 3
(Date:12/21/2014)... offers a wide range of women’s dresses, fashionable accessories ... BellasDress Christmas Sale , offering big discounts on all ... a famous online supplier of women’s dresses; it always ... promotions. The dress experts of the company provide professional ... of offering high quality wedding dresses and women’s special ...
(Date:12/21/2014)... December 21, 2014 AngelWeddingDress.com’s new collection ... is a total of 1,000 new designs in this ... coming spring 2015. , AngelWeddingDress.com promises to ... shoppers with wardrobe essentials while many fashion trends come ... the customer service team at AngelWeddingDress.com is ready to ...
(Date:12/21/2014)... one of the best prom dresses online shops around ... its new collection of 2015 prom dresses, and announced ... prom dresses & other fashionable designs, up to 80 ... dress products and great customer services to its global ... best prom dresses online shops around the world by ...
(Date:12/21/2014)... 2014 Serious Buyer, Andrew Hawley from ... Morrison and the Doors International Ballroom at the Hilton ... be the only time that Morrison's mother would see ... 25, 1967. According to Hawley, “This would be the ... the Alexandria Roller Rink earlier that year and would ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 SCI ... of the issues and systemic barriers for disabled athletes ... Paratriathlon Champion. Scheidies has a condition called juvenile macular ... He describes how he adapted his athletic ambitions to ... his success in triathlon to pioneer the way for ...
Breaking Medicine News(10 mins):Health News:BellasDress.com Announces its BellasDress Christmas Sale 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3
... do not achieve statistical significance, - GPC Biotech schedules conference call ... ... ET/13:30 CET, BOULDER, Colo., MARTINSRIED, Germany, MUNICH, Germany and PRINCETON,N.J., ... AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq:,GPCB) today announced topline ...
... Survival Results Do Not Achieve Statistical Significance, ... SPPI ) licensee, GPC Biotech, today,announced that ... the,treatment of hormone-refractory prostate cancer did not meet ... that the overall survival data for,satraplatin did not ...
... Oct. 30 Barr,Pharmaceuticals, Inc. (NYSE: BRL ... has received tentative approval from the U.S. Food ... Boehringer Ingelheim,Pharmaceuticals, Inc.,s Mirapex(R) (Pramipexole Dihydrochloride) Tablets,0.125mg, 0.25mg, ... it is the,first to file an Abbreviated New ...
... at the Albert Einstein College of Medicine of Yeshiva ... can be successfully treated by targeting the viruses ... 31 issue of PloS One, also raise the possibility ... turn cancerous. , The Einstein researchers used a technique ...
... 79% Growth Over Prior Year Quarter; ... 2008 Guidance, COEUR D,ALENE, Idaho, Oct. 30 ... provider of radiology,solutions to radiology groups across the United ... September 30, 2007. Revenue,grew 79% year-over-year to a record ...
... and OMX Nordic Exchange: EPCT) today announced that Jack ... BioFin Rodman & Renshaw,9th Annual Healthcare Conference on November ... York Palace Hotel in New York. Mr. Talley will ... The presentation will be available live via webcast ...
Cached Medicine News:Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 2Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 3Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 4Health News:GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial 2Health News:GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial 3Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 2Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 3Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 4Health News:Einstein scientists treat cancer as an infectious disease -- with promising results 2Health News:Einstein scientists treat cancer as an infectious disease -- with promising results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 4Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 5Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 6Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 7Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 8Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 9Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 10Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 11Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 12Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 13Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 14Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 15Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 16Health News:EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3
FF 450plus IRu Fundus camera with Visupac / System 431. Digital results in all capture modes and unlimited Visupac software....
The most advanced retinal cameras for fluorescein, color and ICG angiography with full digital imaging capability....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: